期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

三阴性乳腺癌的研究进展 被引量：1

下载PDF
导出
摘要 乳腺癌是女性发病率较高的恶性肿瘤，在我国乳腺癌发病率逐年上升，已经成为妇女健康的最大威胁。
作者 李慧 姜达
机构地区 河北医科大学第四医院东院区肿瘤内科
出处 《肿瘤基础与临床》 2011年第6期540-543,共4页 journal of basic and clinical oncology
关键词 三阴性乳腺癌 生物学特性 化疗 分子靶向治疗 预后
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献26

  • 1袁中玉,王树森,高岩,苏争艳,罗文标,管忠震.305例三阴乳腺癌患者的临床特征及预后因素分析[J].癌症,2008,27(6):561-565. 被引量：161
  • 2葛成华,王世伟,曾和平,陈晔,周海茵,汤旻,叶古祥.腹腔镜在不明原因急腹症中的应用[J].腹腔镜外科杂志,2007,12(2):141-142. 被引量：16
  • 3Liauw JJ, Cheah WK. Laparoscopic management of acute small bowel obstruction[ J]. Asian J Surg ,2005,28 ( 3 ) : 185 - 188.
  • 4Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EG- FR-targeted therapies[ J]. Breast,2007,16( 1 ) :104 - 107.
  • 5Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer clinical features and patterns of recurrence [ J ]. Clin Cancer Res 2007,13 ( 15 Pt 1 ) :4429 - 4434.
  • 6Chattopadhyay S, Zhao R, Krupenko SA, et al. The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line[ J]. Mol Cancer Ther,2006,5 (2) :438 -449.
  • 7Janne PA, Simon GR, Langer C J, et al. Phase Ⅱ trial of pemetrexed and gemeitabine in chemotherapy-naive malignant pleural mesothelio- ma[ J ]. J Clin Oncol,2008,26 ( 9 ) : 1465 - 1471.
  • 8Taylor P, Castagneto B, Dark G, et al. Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelio- ma:results of an International Expanded Access Program [ J ], J Thorac Oncol,2008,3 (7) :764 -771.
  • 9宋海涛,孙刚,马斌林.三阴性乳腺癌的特征[J].肿瘤基础与临床,2011,24(3):270-272. 被引量：2
  • 10李同飞,万云云,张勇.隐性乳腺癌诊疗进展[J].肿瘤基础与临床,2011,24(4):365-366. 被引量：2

二级参考文献175

  • 1吴志扬,张明,黄擎雄,冯平,彭和平,郑小明,曾海峰,邱昌洪,陈伯棠.腹腔镜技术在老年急腹症诊断和治疗中的应用[J].中华医学杂志,2005,85(33):2363-2364. 被引量：13
  • 2张晓明,戚晓东,何时知,王宇.C-erbB-2阴性乳腺癌组织中p53、Ki-67的表达及意义[J].山东医药,2007,47(12):53-54. 被引量：2
  • 3Rakha EA, El-Rehim DA, Paish C, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance[]]. Eur J Cancer, 2006, 42(18): 3149-3156.
  • 4Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes[J]. Clin Cancer Res, 2007, 13(8): 2329-2334.
  • 5Carey LA, Metzger R, Dees EG, et al. American Joint Committee on Cancer tumor-node-metastasls stage after neoadjuvant chemotherapy and breast cancer outcome[J]. J Natl Cancer Inst, 2005 97(15): 1137-1142.
  • 6Ghollet P, Amat S, Belembaogo E, et al. Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer[J]? BrJ Gancer, 2003, 89(7): 1185-1191.
  • 7Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer[J]. Cancer, 2007, 109(1):25-32.
  • 8Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer[J]. Br J Surg, 2007, 94 (10): 1189-1200.
  • 9Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy [J]. Clin Cancer Res, 2005, 11(16): 5678-5685.
  • 10Umemura S, Takekoshi S, Suzuki Y, et al. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression[J]. Oncol Rep, 2005, 14(2): 337-343.

共引文献226

同被引文献23

  • 1Anders CK,Zagar TM,Carey LA. The Management of' Early Stage and Metastatic Triple Negative Breast Cancer:A Review [J]. Hematol Oncol Clin North Am,2013,27(4) :737-749.
  • 2Dent RA ,Lindeman GJ ,Clemons M ,et al. Phase I trial of the oral PARP inhibitor olapm~ib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer[J].Breast Cancer Res, 2013,15 (5) : R88.
  • 3Gonzalez-Angulo AM,Timms KM,Liu S,et al. Incidence and out- come of BRCA mutations in unselected patients with triple recep- tor-negative breast cancer[J]. Clinical Cancer Research,2011,17 (5) : 1082-1089.
  • 4Minckwitz GV,Timms K, Untch M, et al. Prediction of pathological complete response (pCR) by Homologous Recombination Defi- ciency (HRD) after carboplatin-containing neoadjuvant chemother- apy in patients with TNBC :Results from Gepar Sixto[C]. J Clin Oncol,2015,33 (Supp|) : 1004.
  • 5Dent R,Trudeau M,Pritchard KI,et al. Triple negative breast can- cer:Clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007,13(15) :4429-d-434.
  • 6Oakman C,Viale G,Di Leo A. Management of triple negative breast cancer[J]. Breast ,2010,19(5 ) :312-321.
  • 7Adkins FC,Gonzalez-Angulo AM,Lei X,et al. Triple-NegativeBreast Cancer Is Not a Contraindication for Breast Conservation[J]. Annals of Surgical Oncology ,2011,18( 11 ) :3164-3173.
  • 8Abdulkarim BS,Cuartero J,Hanson J,et al. Increased risk of modi- fied radical mastectomy without adjuvant radiation therapy com- pared with breast-conserving therapy[J]. Journal of Clinical On- cology,2011,29(21 ) :2852-2858.
  • 9Wang J,Shi M,Ling R,et al. Adjuvant chemotherapy and radio- therapy in triple-negative breast carcinoma:A prospective ran- domized controlled multi-center trial[J]. Radiotherapy and Oncol- ogy,2011,100(2) :200-204.
  • 10Chen J,Jiang P,Wang HJ,et al. The efficacy of molecular subtyp- ing in predicting postoperative recurrence in breast-conserving therapy:a 15-study meta-analysis [J]. World J Surg Oncol,2014, 12:212.

引证文献1

肿瘤基础与临床
2011年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部